Trevena, Inc. (TRVN)
NASDAQ: TRVN · IEX Real-Time Price · USD
0.238
-0.007 (-3.02%)
At close: Jul 19, 2024, 4:00 PM
0.240
+0.002 (0.84%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Company Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.
Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jan 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Ms. Carrie L. Bourdow |
Contact Details
Address: 955 Chesterbrook Boulevard, Suite 110 Chesterbrook, Pennsylvania 19087 United States | |
| Phone | (610) 354-8840 |
| Website | trevena.com |
Stock Details
| Ticker Symbol | TRVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001429560 |
| CUSIP Number | 89532E109 |
| ISIN Number | US89532E2081 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Carrie L. Bourdow | President, Chief Executive Officer and Chairman |
| Barry Shin | Executive Vice President, Chief Operating Officer and Chief Financial Officer |
| Dr. Mark A. Demitrack M.D. | Senior Vice President and Chief Medical Officer |
| Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board |
| Joel Solomon | Vice President, General Counsel and Chief Compliance Officer |
| Michael Catalano | Vice President of Marketing |
| Robert T. Yoder | Senior Vice President, Chief Business Officer and Head of Commercial Operations |
| Patricia M. Drake | Senior Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K | Current Report |
| May 17, 2024 | DEFR14A | Filing |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | 8-K | Current Report |
| May 3, 2024 | DEFR14A | Filing |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2024 | 8-K | Current Report |
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 9, 2024 | 8-K | Current Report |